JP2018518940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518940A5 JP2018518940A5 JP2017553107A JP2017553107A JP2018518940A5 JP 2018518940 A5 JP2018518940 A5 JP 2018518940A5 JP 2017553107 A JP2017553107 A JP 2017553107A JP 2017553107 A JP2017553107 A JP 2017553107A JP 2018518940 A5 JP2018518940 A5 JP 2018518940A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- antibody
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000185 hemagglutinin Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083700A JP2021121204A (ja) | 2015-04-08 | 2021-05-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
| JP2023116535A JP2023130499A (ja) | 2015-04-08 | 2023-07-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144729P | 2015-04-08 | 2015-04-08 | |
| US62/144,729 | 2015-04-08 | ||
| PCT/US2016/026800 WO2016164835A1 (en) | 2015-04-08 | 2016-04-08 | Humanized influenza monoclonal antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083700A Division JP2021121204A (ja) | 2015-04-08 | 2021-05-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518940A JP2018518940A (ja) | 2018-07-19 |
| JP2018518940A5 true JP2018518940A5 (cg-RX-API-DMAC7.html) | 2019-05-16 |
| JP6960856B2 JP6960856B2 (ja) | 2021-11-05 |
Family
ID=55754481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553107A Active JP6960856B2 (ja) | 2015-04-08 | 2016-04-08 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
| JP2021083700A Pending JP2021121204A (ja) | 2015-04-08 | 2021-05-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
| JP2023116535A Withdrawn JP2023130499A (ja) | 2015-04-08 | 2023-07-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083700A Pending JP2021121204A (ja) | 2015-04-08 | 2021-05-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
| JP2023116535A Withdrawn JP2023130499A (ja) | 2015-04-08 | 2023-07-18 | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11135282B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3280730B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6960856B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102668588B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107750253B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016246065B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2981969C (cg-RX-API-DMAC7.html) |
| IL (2) | IL254951B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016164835A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| WO2015143194A2 (en) * | 2014-03-19 | 2015-09-24 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| WO2018071913A2 (en) | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| MX2020007772A (es) * | 2018-01-26 | 2020-09-18 | Regeneron Pharma | Anticuerpos humanos contra hemaglutinina de influenza. |
| EP3765070A4 (en) | 2018-03-14 | 2021-12-15 | Dana-Farber Cancer Institute, Inc. | SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES |
| SG11202100467VA (en) | 2018-08-13 | 2021-02-25 | Regeneron Pharma | Therapeutic protein selection in simulated in vivo conditions |
| CN109448781B (zh) * | 2018-11-06 | 2021-09-14 | 云南大学 | 一种流感病毒抗原变化的预测方法 |
| CN111423507B (zh) * | 2019-01-10 | 2022-04-15 | 中国科学院分子细胞科学卓越创新中心 | 广谱性中和流感病毒的全人抗体 |
| US11230593B2 (en) | 2019-03-25 | 2022-01-25 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| KR20220113749A (ko) * | 2019-12-11 | 2022-08-16 | 비스테라, 인크. | 인플루엔자를 치료하고 예방하는 조성물 및 방법 |
| IL312538A (en) | 2021-11-05 | 2024-07-01 | Abviro Llc | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
| CN114366809B (zh) * | 2022-01-12 | 2024-07-23 | 广州瑞贝斯药业有限公司 | 一种铝纳米晶递送系统及其结合疫苗抗原分子自组装颗粒佐剂疫苗 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| CN102448986B (zh) * | 2009-05-11 | 2015-11-25 | 克鲁塞尔荷兰公司 | 能中和流感病毒h3n2的人结合分子及其应用 |
| SI2552485T1 (sl) * | 2010-03-26 | 2017-05-31 | Pomona Ricerca S.R.L. | Imunoglobulini polne dolžine igg izotipa, sposobni prepoznave heteropodtipskega nevtralizacijskega epitopa na hemagglutininskem izvornem področju in njih uporaba kot zdravilo proti gripi |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| DK2731967T3 (en) | 2011-07-14 | 2017-01-16 | Janssen Vaccines & Prevention Bv | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS |
| ES2841899T3 (es) * | 2011-07-18 | 2021-07-12 | Inst Res Biomedicine | Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos |
| MX350282B (es) * | 2011-09-30 | 2017-09-01 | Celltrion Inc | Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. |
| US9969794B2 (en) * | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| JP6386465B2 (ja) * | 2012-11-13 | 2018-09-05 | ジェネンテック， インコーポレイテッド | 抗ヘマグルチニン抗体及び使用方法 |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2016
- 2016-04-08 JP JP2017553107A patent/JP6960856B2/ja active Active
- 2016-04-08 AU AU2016246065A patent/AU2016246065B2/en active Active
- 2016-04-08 US US15/564,897 patent/US11135282B2/en active Active
- 2016-04-08 EP EP16716806.1A patent/EP3280730B1/en active Active
- 2016-04-08 KR KR1020177032200A patent/KR102668588B1/ko active Active
- 2016-04-08 WO PCT/US2016/026800 patent/WO2016164835A1/en not_active Ceased
- 2016-04-08 CN CN201680033270.XA patent/CN107750253B/zh active Active
- 2016-04-08 CA CA2981969A patent/CA2981969C/en active Active
-
2017
- 2017-10-09 IL IL254951A patent/IL254951B/en unknown
-
2021
- 2021-05-18 JP JP2021083700A patent/JP2021121204A/ja active Pending
- 2021-08-18 US US17/405,748 patent/US12076390B2/en active Active
- 2021-09-03 AU AU2021225240A patent/AU2021225240A1/en not_active Abandoned
- 2021-09-09 IL IL286208A patent/IL286208A/en unknown
-
2023
- 2023-07-18 JP JP2023116535A patent/JP2023130499A/ja not_active Withdrawn